Is the Trend Turning for This Psychedelic Stock?

Contributed Opinion
  ()
Technical analyst Clive Maund charts Delic Inc. and explains why he considers the stock attractive at this point. read more >

Merck Selects Rapidly Growing Psychedelic Medicine Company as Key Research Site

  ()
Novamind runs clinics, research sites and therapeutic retreats and is positioning itself for expansion. read more >

Health Tech Company Acquiring Ontario Health Management Firm, Its Largest Transaction Ever

Research Report
  ()
A Research Capital Corp. report discusses CloudMD Software & Services' acquisition of Oncidium, "one of Canada's leading health management companies." read more >

Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3

  ()
Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia. read more >

Biotech Company Acquires Therapeutics Firm, Gains 'Gem' in the Portfolio

Research Report
  ()
Dawson James Securities advised it is maintaining its "Buy" rating after Sorrento Therapeutics announced the acquisition of ACEA Therapeutics for $38 million in stock. read more >

Novocure Shares Climb 50% on Acceleration of Phase 3 Lung Cancer Trial

  ()
Novocure Ltd. shares reached a new 52-week high after the company reported an update from its Phase 3 Pivotal LUNAR trial of tumor treating electrical fields in non-small cell lung cancer. read more >

Nuance Communications Shares Rise 16% on $19.7 Billion Buyout Bid by Microsoft

  ()
Nuance Communications shares reached a new 52-week high after the company reported that it agreed to be acquired by Microsoft in an all cash transaction for $56 per share. read more >

Affimed NV Shares Rise 20% on Initial Data from Phase 1 R/R CD30-Positive Lymphoma Trial

  ()
Affimed NV shares reached a new 52-week high price after the company presented initial data from a Phase 1 trial of its AFM13 that shows potential to help NK cells target and destroy cancer cells. read more >

Biohaven Expects Net Revenue of $43.8 Million in Q1 for Its Migraine Medicine

  ()
Biohaven Pharmaceutical shares traded 10% higher after the company reported that in Q1/21 net product revenue for its migraine drug NURTEC ODT is estimated to be approximately $43.8 million. read more >

Biopharma's Phase 2b/3 Alzheimer's Disease Trial Approved to Continue

Research Report
  ()
Anavex Life Sciences' study, its drug's mechanism of action and the company's upcoming catalysts are covered in a Dawson James Securities report. read more >

Gene Therapy Restoring Light Sensitivity 'Showed Impressive Dose-Response Improvements'

Research Report
  ()
Roth Capital Partners advised that Applied Genetic Technologies co-development of BS01 with Bionic Sight "validates its gene therapy capabilities." read more >

Nano-X Imaging Receives Go Ahead from FDA for Single Source Digital X-Ray

  ()
Shares of Nano-X Imaging Ltd. traded 17% higher after the company reported that the FDA has granted 510(k) approval for its single source ARC digital x-ray. read more >

United Therapeutics Shares Rise 15% as FDA Clears Pathway to Launch Tyvaso to Treat PH-ILD

  ()
United Therapeutics shares reached a new 52-week high after the firm reported that the U.S. FDA granted approval to commercially launch its TyvasoŽ Inhalation Solution to treat patients with pulmonary hypertension associated with interstitial lung disease. read more >

Expert Investing Ideas

"Final results from AGN's Phase 2b COVID-19 trial are expected soon."

–André Uddin, Research Capital Corporation


"AGN is to continue a number of preclinical studies of DMT for stroke."

–André Uddin, Research Capital Corporation


"AGN [shares] are now in a vigorous uptrend."

–Clive Maund, CliveMaund.com


"Multiple players are at the table with PMN for a licensing deal."

–André Uddin, Research Capital Corporation


"PMN is to initiate a Phase 1 PMN310 study for Alzheimer's in H2/19."

–André Uddin, Research Capital Corporation


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Coverage Initiated on Health & Wellness Firm About to Launch Retail Sales, Sees 'Substantial Upside Potential'

Research Report
  ()
Clarus Securities' initiation report on Rritual Superfoods views the company "as an attractive growth story for investors looking to gain exposure to a large and rapidly growing functional food and beverages market." read more >
News Update

Pharmaceutical Development Company Added to First Psychedelic Stock Index ETF

News Update
  ()
Being included in the Horizons Psychedelic Stock Index Exchange Traded Fund will afford Algernon Pharmaceuticals greater investor exposure. read more >

Shockwave Medical Reports 100% Increase in Preliminary Q1 Revenue

  ()
Shockwave Medical Inc. shares gained 19% after the company announced that sales of its recently launched C2 Coronary IVL System are growing steadily and are driving revenue growth. read more >